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Abstract
Recipients of kidney transplantation have elevated risk of developing cancer. There are limited 
data on cancer risk in recipients of kidney retransplantation.
We used data from the Transplant Cancer Match Study, which links the U.S. transplant registry 
with 15 cancer registries. Cancer incidence in recipients of kidney retransplantation and primary 
kidney transplants was compared utilizing Poisson regression, adjusting for demographic and 
medical characteristics.
We assessed 109,224 primary recipients and 6,621 retransplants. Compared to primary recipients, 
retransplants were younger (median age 40 vs. 46 years), had higher PRA, and more often 
received induction with polyclonal antibodies (43% vs. 25%). A total of 5,757 cancers were 
observed in primary recipients and 245 in retransplants. Overall cancer risk was similar in 
retransplants compared with primary recipients (incidence rate ratio [IRR] 1.06, 95%CI 0.93-1.20, 
adjusted for age, gender, race/ethnicity, PRA, and use of polyclonal induction). However, renal 
cell carcinoma (RCC) occurred in excess among retransplants (adjusted IRR 2.03, 95%CI 
1.45-2.77), based on 514 cases in primary recipients and 43 cases in retransplants.
Overall cancer risk did not differ in retransplants compared to primary recipients. Increased risk of 
RCC may be explained by the presence of acquired cystic kidney disease, which is more likely to 
develop with additional time with kidney disease and time spent on dialysis waiting for 
retransplantation.
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Introduction
Risk of cancer is elevated among recipients of solid organ transplants (1, 2, 3), including 
kidney transplants. In large part, this increased risk occurs because of immunosuppressive 
therapy used to prevent rejection. Some of the cancers for which risk is elevated are caused 
by infections (e.g., non-Hodgkin lymphoma, which is caused by Epstein-Barr virus). Among 
kidney recipients, risk is also increased for renal cell carcinoma (RCC), which often arises in 
one of the native kidneys.
Patients undergoing retransplantation after a failed first kidney transplant can be 
immunologically more challenging than primary kidney recipients, because they more often 
present with higher panel reactive antibody (PRA) levels, therefore placing them at higher 
risk for rejection (4, 5).
Nonetheless, due to significant progress in immunology over the last 2 decades leading to 
better prevention and treatment of acute rejection, more patients with failed transplants are 
acceptable to undergo retransplantation. In fact, between 1990 and 2007, the number of 
kidney retransplants doubled in the United States (6). Approximately 15% of the more than 
100,000 patients currently on the U.S. waiting list for kidney transplantation already had a 
previous kidney transplant (7).
Although the positive association of cancer with kidney transplantation is established, little 
is known regarding cancer risk in recipients of kidney retransplantation. Prior exposure to 
immunosuppression and differences in immunologic status of recipients of kidney 
retransplantation could have an impact in the risk of cancer. For example, retransplantation 
may be associated with higher risk of cancer than seen in primary transplants due to more 
frequent use of polyclonal antibodies for induction, treatment of rejection, or prolonged 
exposure to immunosuppressants. On the other hand, because people who undergo 
retransplantation may be selected for certain characteristics (e.g., based on a younger age or 
favorable underlying medical condition), their cancer risk might be lower than seen in the 
group of primary kidney recipients.
Information regarding cancer risk following kidney retransplantation may lead to changes in 
patient care, perhaps related to counseling and surveillance. The goal of this study is to 
compare cancer risk in recipients of kidney retransplantation with risk in recipients of a 
primary kidney transplant.
Methods
We used data from the TCM Study, which has been described in detail elsewhere 
(www.transplantmatch.cancer.gov) (2). Briefly, the Scientific Registry of Transplant 
Recipients (SRTR) was linked to 15 state and regional cancer registries, together covering 
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approximately 50% of U.S. kidney transplants during 1987-2009. The cancer registries 
cover the states of California, Colorado, Connecticut, Georgia, Hawaii, Illinois, Iowa, 
Michigan, New Jersey, New York, North Carolina, and Texas, as well as the Seattle-Puget 
Sound area of Washington State. The study was approved by the human subjects committees 
of the National Cancer Institute and, as required, by the participating cancer registries. The 
clinical and research activities being reported are consistent with the Principles of Istanbul 
as outlined in the “Declaration of Istanbul on Organ Trafficking and Transplant Tourism.”
The TCM Study includes 121,223 kidney-only transplants with follow-up information on 
cancer from the cancer registries. All causes of CKD were included. We excluded 766 
transplants in people with unknown race or race outside one of the four major groups, 7 
transplants that were a fifth transplant or higher in sequence, 4301 transplants preceded by 
non-kidney transplants, and 304 transplants in people who had transplants within 180 days 
following a prior transplant. Following the exclusions, there remained 115,845 transplants.
We compared primary kidney transplants and kidney retransplants with respect to age and 
year at transplant, race/ethnicity, gender, type of transplant (living donor vs. deceased-
donor), use of induction medications, and immunologic risk assessed by PRA. We evaluated 
dialysis vintage as the duration of dialysis treatment before kidney transplantation. For 
retransplants, dialysis vintage was the period of dialysis after failure of the preceding 
transplant until retransplant. We also calculated the total dialysis vintage, which was the sum 
of time on dialysis before the primary transplant and any retransplants. Because patients 
with more than one transplant are included multiple times, statistical comparisons of these 
characteristics of primary kidney transplants and retransplants were accomplished using 
generalized linear models.
All invasive cancers were identified using the linked cancer registry data and classified by 
the Surveillance Epidemiology, and End Results program “site recode with Kaposi sarcoma 
and mesothelioma” with minor modifications (2, 8). For both primary transplants and 
retransplants, follow-up started at the later of transplantation or start of cancer registry 
coverage, and ended at death, graft failure, retransplantation, loss to follow-up by the 
transplant registry, or end of cancer registry coverage, whichever occurred first. Cancer 
incidence was defined as the number of cancer cases observed divided by person-time at 
risk.
In statistical analyses of cancer risk, the transplant was considered the unit of analysis. We 
used Poisson regression to calculate unadjusted incidence rate ratios (IRR) comparing 
cancer risk following retransplant to risk among primary transplant recipients. Because 
many individual cancer types were uncommon, with few outcomes among retransplant 
recipients, we also created categories of cancer by organ system to achieve an acceptable 
number of cases that would permit age-adjusted analyses. In final multivariate models for 
cancer overall and RCC, we adjusted IRRs for demographic characteristics and factors that 
differed between the retransplants and primary transplants, specifically, age, gender, race/
ethnicity, use of polyclonal antibody induction, and PRA. A p-value of <0.05 was 
considered statistically significant, although given the number of comparisons that we made, 
we emphasize associations with greater statistical significance.
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We evaluated 109,224 primary kidney transplants and 6,621 kidney retransplants (6,309 
second transplants, 296 third transplants, and 16 fourth transplants) in the U.S., followed 
between 1987 and 2009 (Table 1). Mean follow-up was 4.6, 3.7, 2.9, and 3.4 years for 
primary, second, third, and fourth transplants, respectively. More than 50% of primary 
transplants and more than 70% of the retransplants were performed between 2000 and 2009.
Compared with primary transplant recipients, retransplant recipients were substantially 
younger (median age at transplant 40 vs. 46 years), had a higher prevalence of glomerular 
disease, and a lower prevalence of diabetes mellitus and hypertension as the cause of chronic 
kidney disease (CKD). Compared to primary transplants, the percentage of non-Hispanic 
whites was higher in retransplants, while the percentage of racial/ethnic minorities was 
lower. Dialysis vintage immediately prior to transplantation was similar in primary 
transplant and retransplant recipients (median 645 vs. 731 days), but total dialysis vintage 
was longer for recipients of retransplantation (i.e., sum of time on dialysis before all prior 
transplants: median 1402 days).
Deceased donor kidneys were used more frequently in retransplantation (71%) than primary 
transplants (64%). PRA was higher in retransplants, and a larger fraction were highly 
sensitized (i.e., approximately 30% of retransplant patients had a PRA >80%, vs. 5% for 
primary transplants). More recipients of retransplants received a kidney from a 0 HLA 
mismatch donor (17%) compared to primary transplants (10%). Induction with polyclonal 
antibodies was employed more often in recipients of retransplantation (43%) compared to 
primary transplants (25%) (Table 1).
A total of 5,757 and 245 cancers were observed in recipients of primary transplants and 
retransplants, respectively (Table 2). Overall, cancer risk was lower in recipients of 
retransplantation (unadjusted incidence rate ratio [IRR] 0.87, 95%CI 0.77-0.99). Among 
specific cancer types, incidence was lower in recipients of retransplantation for cancers of 
the prostate (IRR 0.61, 95%CI 0.37-0.94), lung (IRR 0.65, 95%CI 0.4-0.98), colon and 
rectum (IRR 0.53, 95%CI 0.25-0.97), and breast (IRR 0.55, 95%CI 0.26-0.99), although 
these associations were of borderline significance. In contrast, only cancers of the kidney/
renal pelvis showed significantly higher incidence in retransplants compared to primary 
transplants (IRR 1.61, 95%CI 1.19-2.12, p=0.0012). Most of these kidney cancers (80.5%) 
were RCCs, and as shown in Table 2, this excess risk in retransplantation was present 
specifically for RCC (IRR 1.72, 95%CI 1.24-2.31, p=0.0007).
These unadjusted IRRs partly reflect differences between primary transplants and 
retransplants shown in Table 1, especially the younger age of retransplants. Because many 
cancers were rare in recipients of a retransplant, we grouped cancers by organ/system to 
permit age-adjusted analysis. In these age-adjusted models (Table 3), retransplantation was 
no longer associated with a lower risk of cancer overall (IRR 1.06, 95%CI 0.93-1.20). As 
shown in Table 3, there were suggestive deficits of gastrointestinal tract and breast cancers, 
although these deficits were not significant. Notably, retransplantation was associated with 
higher risk of cancers of the kidney, renal pelvis, and bladder (age-adjusted IRR 1.74, 
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95%CI 1.33-2.29). We also observed a higher risk for leukemias (age-adjusted IRR 2.30, 
95%CI 1.05-5.02). All other age-adjusted analyses for cancers combined by organ/system 
did not yield statistical significance (Table 3).
In a multivariate model with adjustment for age as well as gender, race/ethnicity, use of 
polyclonal antibody induction, and PRA, recipients of a retransplant had a similar risk for 
cancer overall (IRR 1.06, 95% CI 0.93-1.20) but an elevated risk for RCC (IRR 2.03, 95%CI 
1.45-2.77, p<0.0001), compared to recipients of a primary transplant. RCCs were diagnosed 
at similar stage in primary and retransplant recipients (p=0.28), with cancers presenting at 
localized stage in 78% and 90% of recipients, respectively. RCC grade distribution was also 
similar between both groups (p=0.42). Overall, retransplants had a longer time on dialysis 
before being diagnosed with RCC, as expected (total dialysis vintage including time on 
dialysis before primary transplant and before retransplant: median 1690 vs. 902 days). 
Nonetheless, retransplant recipients still had a higher risk of RCC than primary recipients 
after adjustment for age at transplant, gender, race/ethnicity, use of polyclonal induction 
therapy, PRA, and total dialysis vintage (IRR 1.81, 95%CI 1.29-2.47). Finally, when the 
time from most recent transplant to RCC diagnosis was examined, we observed a shorter 
interval for retransplants than primary transplants (median 790 vs. 1342 days, respectively.
Discussion
In this study, we demonstrated a similar overall risk of malignancy for recipients of kidney 
retransplantation compared to recipients of primary transplants. In unadjusted analyses, 
lower risk was apparent for several common cancers, including cancers of the lung, 
colorectum, prostate, and breast. However, these excesses were of marginal statistical 
significance, and some may have been due to differences between the retransplant and 
primary transplant groups. Importantly, after multivariate adjustment for demographic and 
clinical differences between retransplants and primary transplants, no difference in overall 
cancer risk was present. Notably, among all malignancies, only RCC was found at a higher 
incidence in retransplants.
As observed in our study, recipients of a retransplant have higher PRA than recipients of a 
primary transplant, and as a result of this greater sensitization, are more frequently treated 
with polyclonal antibody induction. In a recent publication by Lim et al. examining the 
impact of PRA on cancer outcomes in kidney transplantation, a higher risk of cancer was 
observed in patients with >80% PRA compared to 0% (9). Given a greater degree of 
immunosuppression, one might expect recipients of a retransplant to have a higher risk of 
cancer, particularly for cancers related to infectious causes such as anogenital cancers 
(caused by human papillomavirus [HPV]) and non-Hodgkin lymphoma (caused by Epstein-
Barr virus). We did not observe that, however. Our findings differ from those in a recent 
publication by Madeleine et al. which, like our study, also used data from the TCM Study 
(10). They demonstrated a higher risk of anal and vulvar cancer for retransplants compared 
to primary transplants. The main difference from our study is that the previous cohort 
included all types of solid organ transplants, while our analysis focused only on kidney 
transplants. By restricting to one organ type, our comparison of cancer risk in retransplants 
and primary transplants may be less prone to bias. Nonetheless, the number of HPV-related 
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cancers in our study was small, resulting in wide confidence intervals, so that we cannot rule 
out an increased risk associated with retransplantation.
In unadjusted analyses, we saw lower risk for some cancers in retransplants, which we 
attribute in large part to the younger age of retransplant recipients. A suggestion of lower 
risk of breast cancer and gastrointestinal tract cancers remained after adjustment for age, 
although the associations were no longer significant. After adjusting only for age, and in the 
final multivariate model adjusting for sex, age, race/ethnicity, use of polyclonal antibody 
induction, and PRA, the overall decreased risk of cancer was no longer apparent (both 
adjusted IRRs 1.06).
Kidney recipients have an almost 7-fold higher risk of kidney cancer than seen in the general 
population (2). In the present study, we demonstrate that recipients of retransplantation have 
a two-fold higher incidence of RCC than primary recipients (adjusted IRR 2.03). Recently, 
Wong et al. examined dialysis vintage and risk of cancer after transplantation in the 
ANZDATA registry, and found an association for urinary tract cancers (11). An elevated 
risk of RCC is present in patients with CKD, with further increase in risk as CKD advances 
(12), and risk is quite increased in patients on dialysis and among kidney transplant 
recipients (1, 2, 13).
Acquired cystic kidney disease (ACKD) is highly prevalent in patients with CKD. In 
ACKD, cysts originate in dilated renal tubules, and increase in number over time, even 
before the need for renal replacement therapy (14). After initiation of dialysis, the 
prevalence of cysts continues to increase, with the majority of patients having cysts after 10 
years of dialysis, suggesting that the duration of CKD or dialysis is the main risk for 
development of renal cysts (15). ACKD is a risk factor for RCC (16), as RCCs can arise 
within these complex cysts (17). Prolonged dialysis and development of ACKD may partly 
explain the high risk of RCC in retransplant recipients, but unfortunately our study lacked 
data on the presence of ACKD.
Furthermore, even though retransplants in our study had a longer dialysis vintage than 
primary transplants, the excess risk of RCC was still present after we adjusted for dialysis 
vintage. Interestingly, recipients of retransplants had a shorter interval from transplant to 
RCC diagnosis compared to primary transplant recipients. This finding might suggest a 
more aggressive course of RCC after retransplantation, but whether there is a biological 
mechanism that explains this finding, or instead it reflects differences in duration of follow-
up, is not known. Due to a higher risk for RCC in retransplants associated with a shorter 
interval from transplant to diagnosis, we compared grading and staging of RCC between 
both groups, but found no significant differences. A limitation of our study is that we could 
not determine that the RCCs that developed actually occurred in the diseased native kidneys, 
although we suspect that was the case for the majority (13).
In our age-adjusted analyses, we observed a higher risk for leukemias in retransplant 
recipients compared to primary kidney recipients. However, this increased risk was due to 
an excess of several types of leukemia. These malignancies likely do not all have the same 
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etiology, but the small number of cases hindered a more detailed analysis. Given the rarity 
of leukemia, the clinical significance of this finding is uncertain.
This study has several strengths, including the availability of population-based data on 
transplant recipients and linkage to 15 cancer registries, which together cover almost half of 
all U.S. kidney transplants. This permitted inclusion of a large and representative population 
of kidney recipients and complete ascertainment of cancer outcomes. Also, our statistical 
adjustment allowed us to control for demographic and medical differences between the 
retransplants and primary recipients. Limitations include the lack of availability on some 
cancer risk factors (e.g., tobacco use) which may have confounded some analyses. Even 
though we made multiple comparisons in assessing risk for numerous cancers, the 
association with RCC was highly significant, arguing against chance as an explanation for 
that finding.
In conclusion, overall cancer risk is not increased among kidney retransplant recipients 
compared to primary kidney recipients, but the risk of RCC is elevated. Our findings should 
stimulate further investigation of RCC in retransplantation. It is likely that the majority of 
the RCC diagnoses occur in patients with pre-existing ACKD. Given the elevated risk of 
RCC, it may be beneficial to screen for this cancer in retransplant recipients, although a 
careful analysis of cost and benefits of screening should be conducted before implementing 
such an approach.
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Table 1
Characteristics of U.S. Kidney Transplant Recipients
Characteristic Primary Transplants (% of total) Retransplants (% of total) P-value
Calendar Year of Transplant 1987-1994 21,249 (19.45) 544 ( 8.22) <.0001
1995-1999 27,559 (25.23) 1,303 (19.68)
2000-2004 33,486 (30.66) 2,466 (37.25)
2005-2009 26,930 (24.66) 2,308 (34.86)
Sex Male 65,225 (59.72) 3,790 (57.24) <.0001
Female 43,999 (40.28) 2,831 (42.76)
Age at Transplant, years 0-17 6,338 ( 5.80) 417 ( 6.30) <.0001
18-34 21,538 (19.72) 1,997 (30.16)
35-49 34,981 (32.03) 2,462 (37.18)
50-64 35,839 (32.81) 1,509 (22.79)
65+ 10,528 ( 9.64) 236 ( 3.56)
Reason For Transplant Glomerular Disease 31,643 (28.97) 2,848 (43.01) <.0001
Diabetes 18,176 (16.64) 488 ( 7.37)
Polycystic Kidneys 9,815 ( 8.99) 439 ( 6.63)
Hypertension 18,623 (17.05) 820 (12.38)
Vascular Disease 4,348 ( 3.98) 221 ( 3.34)
Congenital/Rare Disorders 3,392 ( 3.11) 414 ( 6.25)
Tubular/Interstitial Disease 5,727 ( 5.24) 516 ( 7.79)
Other/Unknown 17,500 (16.02) 875 (13.22)
Race/Ethnicity White, Non-Hispanic 58,153 (53.24) 3,960 (59.81)
Black, Non-Hispanic 24,562 (22.49) 1,365 (20.62)
Hispanic 19,064 (17.45) 1,018 (15.38)
Asian/Pacific Islander 7,445 ( 6.82) 278 ( 4.20)
Dialysis Vintage (Days) 0 – 244 26,030 (23.83) 1,492 (22.53) <.0001
245 – 650 25,872 (23.69) 1,546 (23.35)
651 – 1316 25,815 (23.63) 1,663 (25.12)
1317+ 25,550 (23.39) 1,905 (28.77)
Missing 5,957 (5.45) 15 ( 0.23)
Total Dialysis Vintage(Days) 0 - 244 26,028 (23.83) 424 ( 6.40) <.0001
245 - 650 25,872 (23.69) 923 (13.94)
651 - 1316 27,121 (24.83) 1,536 (23.20)
1317+ 24,246 (22.20) 3,042 (45.94)
Missing 5,957 (5.45) 696 (10.51)
Donor Type Deceased 69,458 (63.59) 4,679 (70.67) <.0001
Living 39,766 (36.41) 1,942 (29.33)
HLA Mismatch 0 11,452 (10.48) 1,133 (17.11) <.0001
1-2 18,882 (17.29) 1,183 (17.87)
3-4 45,005 (41.20) 2,499 (37.74)
5-6 32,805 (30.03) 1,775 (26.81)
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Characteristic Primary Transplants (% of total) Retransplants (% of total) P-value
Missing 1,080 (0.99) 31 (0.47)
PRA 0 51,506 (47.16) 1,255 (18.95) <.0001
1-79 50,073 (45.84) 3,328 (50.26)
80+ 5,776 ( 5.29) 1,978 (29.87)
Missing 1,869 ( 1.71) 60 (0.91)
Induction Therapy Polyclonal antibody 27,459 (25.14) 2,867 (43.30) <.0001
Monoclonal antibody (OKT3) 6,287 ( 5.76) 393 ( 5.94) 0.5399
Anti-IL2R 24,493 (22.42) 1,286 (19.42) <.0001
Abbreviations: PRA panel reactive antibody, Anti-IL2R interleukin- 2 receptor antibody
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